bowel syndrome News
-
Atmo Biosciences’ ingestible gas-sensing capsule to be used in Swedish IBS trial led by Professor Magnus Simrén
Atmo Biosciences’ world-first ingestible gas-sensing capsule is being used in a clinical trial led by renowned gastroenterologist Professor Magnus Simrén currently underway at Sweden’s University of Gothenburg. The trial named “The effects of carbohydrates in irritable bowel syndrome” is using the Atmo Gas Capsule digital biomarker platform to profile gases within ...
-
Human trials underway for first generation Atmo Gas Capsule
Two human trials of Atmo Biosciences’ ingestible gas-sensing capsule have begun. The first trial is being conducted at Monash University and the Alfred Hospital in Melbourne, Australia, in collaboration with the research team led by Professor Peter Gibson and Professor Jane Muir. The trial will investigate motility and transit time through the gastrointestinal tract for the Atmo Gas ...
-
Atmo Biosciences signs deal with RMIT University to commercialize ingestible gas-sensing capsule for gut health
Atmo Biosciences has signed a licensing deal with RMIT University securing the exclusive worldwide rights to commercialize a ground-breaking ingestible gas-sensing capsule. The Atmo Gas Capsule is set to revolutionize how doctors diagnose and treat common gastrointestinal (GI) disorders by offering a non-invasive, low-cost, and more accurate alternative to current technologies. Patients with ...
-
Creative Enzymes Revolutionizes the Probiotics Industry with Bacillus Coagulans Freeze Dried Powder
Creative Enzymes, a professional enzyme provider located in New York, USA, proudly unveils its high-quality product, Bacillus Coagulans Freeze Dried Powder. This cutting-edge probiotic powder not only offers a multitude of health benefits but also ushers in unprecedented opportunities for the food and pharmaceutical industries. Bacillus Coagulans, a resilient and spore-forming bacterium, has ...
-
EndoLogic Acquires Renzapride from Alizyme, plc
EndoLogic, a company focused on the development and commercialization of products that treat gastrointestinal diseases, has acquired the worldwide rights to the clinical-stage asset, renzapride, from Alizyme, plc. Renzapride has been in clinical development for use as a prokinetic agent for the gastrointestinal tract. EndoLogic plans on developing the compound for the treatment of gastroparesis. ...
-
G-Tech Medical Receives FDA Clearance for its Gastrointestinal Motility Monitoring System
MOUNTAIN VIEW, Calif., January 13, 2022 – G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its Wireless Patch System (WPS) for non-invasive myoelectric activity measurement. The G-Tech WPS is a tool that provides gastric and intestinal myoelectrical ...
-
Fecal biomarkers - diagnostic possibilities in the context of inflammatory bowel disease
Inflammatory bowel disease (IBD), mainly divided into Crohn's disease (CD) and ulcerative colitis (UC), are diseases whose causes are not fully understood and for which there is no cure. The chronic progression of IBD is characterized by periods of symptomatic relapses and symptom-free phases. During relapses, acute inflammation occurs in the bowel of IBD patients, leading to typical symptoms ...
-
The Ultimate List of Attractive MedTech M&A Targets
Updated May 12, 2021 to reflect 10 new additions, based on recent analyst reports. We’ve also updated the existing companies on the list to reflect recent business developments. From time to time, medtech analysts will call out companies in the private sector that they believe investors should be keeping tabs on. Here is our ultimate list, compiled from analyst reports, of private ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you